ProCyte Interviews With The Wall Street Transcript

Apr 10, 2001, 01:00 ET from ProCyte Corporation

    REDMOND, Wash., April 10 /PRNewswire/ -- ProCyte Corporation,
 (OTC Bulletin Board:   PRCY), a leading skin care and tissue repair company
 based on patented Copper Peptide technologies, today reported that The Wall
 Street Transcript has published an in-depth interview with Jack Clifford,
 President and CEO of ProCyte in which he talks at length about the company's
 future.
     The insightful interview provides an overview of the company and its focus
 on the GHK Copper Peptide technology.  Jack Clifford reviews the Neutrogena
 (JNJ) license agreement and their recent launch of the innovative Visibly
 Firm(TM) product line that contains the ProCyte Copper Peptide technology
 which they call Active Copper(TM).  Positioned to quickly capitalize on the
 rapidly expanding baby boomer market, Mr. Clifford also discusses the
 company's strategic plans and other licensing opportunities.
     There are forward looking comments about 2001 revenues and the potential
 for the company to become profitable.  The interview also provides a glimpse
 of revenues and profits in the future years.
     This interview is part of an 80-page Life Sciences Issue available at
 http://www.twst.com/info/info323.htm , or by calling 212-952-7433. The entire
 interview is available free online at http://www.twst.com/ceos.htm .
     ProCyte will report its first quarter earnings on April 18, 2001.  A
 conference call is scheduled for 1:00 p.m. (PDT) at 800-521-5499 access
 # 998555.
 
     About ProCyte:
     ProCyte Corporation is a healthcare products company that develops and
 markets products for skin health, hair care and wound care. The Company's
 comprehensive therapeutic and anti-aging skin care lines include products for
 post-procedure treatments and anti-aging applications, as well as products for
 thinning hair. Many products incorporate the ProCyte patented, clinically
 proven Copper Peptide technology, which is marketed directly to Dermatologists
 and Cosmetic physicians through its own sales force and through distribution
 partners and licensees for wound care and consumer market segments.
     This report may contain forward-looking statements that are subject to
 certain risks and uncertainties that could cause actual results to differ
 materially from those projected.  This report should be read in conjunction
 with the Company's annual report on Form 10-K and it's quarterly reports on
 Form 10-Q.  The Company's results may vary significantly from quarter to
 quarter and will depend, among other factors, on product launches and market
 acceptance, manufacturing contracts, and distribution agreements.
 
     CONTACT:  Jack Clifford, Chairman/CEO of ProCyte Corporation,
 425-869-1239.
 
 

SOURCE ProCyte Corporation
    REDMOND, Wash., April 10 /PRNewswire/ -- ProCyte Corporation,
 (OTC Bulletin Board:   PRCY), a leading skin care and tissue repair company
 based on patented Copper Peptide technologies, today reported that The Wall
 Street Transcript has published an in-depth interview with Jack Clifford,
 President and CEO of ProCyte in which he talks at length about the company's
 future.
     The insightful interview provides an overview of the company and its focus
 on the GHK Copper Peptide technology.  Jack Clifford reviews the Neutrogena
 (JNJ) license agreement and their recent launch of the innovative Visibly
 Firm(TM) product line that contains the ProCyte Copper Peptide technology
 which they call Active Copper(TM).  Positioned to quickly capitalize on the
 rapidly expanding baby boomer market, Mr. Clifford also discusses the
 company's strategic plans and other licensing opportunities.
     There are forward looking comments about 2001 revenues and the potential
 for the company to become profitable.  The interview also provides a glimpse
 of revenues and profits in the future years.
     This interview is part of an 80-page Life Sciences Issue available at
 http://www.twst.com/info/info323.htm , or by calling 212-952-7433. The entire
 interview is available free online at http://www.twst.com/ceos.htm .
     ProCyte will report its first quarter earnings on April 18, 2001.  A
 conference call is scheduled for 1:00 p.m. (PDT) at 800-521-5499 access
 # 998555.
 
     About ProCyte:
     ProCyte Corporation is a healthcare products company that develops and
 markets products for skin health, hair care and wound care. The Company's
 comprehensive therapeutic and anti-aging skin care lines include products for
 post-procedure treatments and anti-aging applications, as well as products for
 thinning hair. Many products incorporate the ProCyte patented, clinically
 proven Copper Peptide technology, which is marketed directly to Dermatologists
 and Cosmetic physicians through its own sales force and through distribution
 partners and licensees for wound care and consumer market segments.
     This report may contain forward-looking statements that are subject to
 certain risks and uncertainties that could cause actual results to differ
 materially from those projected.  This report should be read in conjunction
 with the Company's annual report on Form 10-K and it's quarterly reports on
 Form 10-Q.  The Company's results may vary significantly from quarter to
 quarter and will depend, among other factors, on product launches and market
 acceptance, manufacturing contracts, and distribution agreements.
 
     CONTACT:  Jack Clifford, Chairman/CEO of ProCyte Corporation,
 425-869-1239.
 
 SOURCE  ProCyte Corporation